BNTX to Boost Oncology Pipeline With Biotheus Acquisition
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases. With the acquisition,
Merck MRK announced that it has entered into an exclusive licensing deal with China-based privately-held biotech company ...
Analysts fell to the sidelines weighing in on BioNTech SE (BNTX – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback